ReviewIndian journal of psychiatry2026
Neuromodulation therapies in the management of tardive dyskinesia: A scoping review.
Review in Indian journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tardive dyskinesia (TD) comprises persistent involuntary movements that usually emerge after sustained treatment with dopamine receptor blocking agents. Objectives: Although vesicular monoamine transporter 2 (VMAT2) inhibitors have expanded treatment options, a proportion of patients continue to experience disabling symptoms, prompting interest in neuromodulator interventions. Methods: Evidence was retrieved from three databases, PubMed, Scopus, and Web of Science, with coverage limited to English-language publications dated January 2000-September 2025. Studies reporting the use of deep brain stimulation (DBS), electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial direct current stimulation (tDCS) for TD were charted, and the extracted findings were grouped according to neuromodulation modality following Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidance. Results: Included studies comprised DBS, ECT, rTMS, and tDCS reports, with evidence ranging from randomized controlled trials to case reports. Globus pallidus internus deep brain stimulation (GPi-DBS) showed the most consistent and durable benefit, with prospective studies reporting approximately 56%-63% improvement on extrapyramidal symptom rating scale (ESRS) and abnormal involuntary movement scale (AIMS) outcomes. ECT was associated with AIMS improvement in one small retrospective study and three case-reports. rTMS showed preliminary benefit, although protocols were heterogeneous and TD-specific controlled outcomes were limited. tDCS showed emerging benefit, particularly for facial-oral dyskinesia. Conclusion: Neuromodulation is a promising adjunctive option for refractory TD. GPi-DBS has the strongest evidence, whereas rTMS and tDCS remain investigational and require larger controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.